For decades, the U.S. government maintained an almost total wall of silence around any medical potential in cannabis. Then, quietly and without a press conference, the country’s own principal cancer research agency updated its website with a sentence that had never appeared there before: cannabis has been shown to kill cancer cells in the laboratory.
What the evidence shows
- Cannabis and cancer cells: The National Cancer Institute published language on its official website confirming that cannabis has been shown to kill cancer cells in laboratory settings — a remarkable acknowledgment from a U.S. federal agency.
- Preclinical cannabinoid research: Studies cited by the NCI found that cannabinoids inhibit tumor growth in mice and rats by causing cell death, blocking cell proliferation, and cutting off the blood supply that tumors depend on to grow.
- FDA approval status: Despite the findings, the U.S. Food and Drug Administration had not approved cannabis for treating cancer as of 2015 C.E. — only two cannabinoids, dronabinol and nabilone, held approval for managing chemotherapy-related nausea and vomiting.
Why this moment mattered
The NCI is not a fringe organization. It is mandated by U.S. law to serve as the federal government’s principal agency for cancer research and public education. When it added language to its website acknowledging that cannabis kills cancer cells in lab conditions, it represented the first time a major arm of the U.S. government had publicly aligned itself with that body of research.
That may sound like a small bureaucratic update. It was not.
Cannabis remained — and as of this writing, still remains — a Schedule I controlled substance under federal law, a classification reserved for drugs with no accepted medical use and a high potential for abuse. The NCI acknowledgment sat in direct tension with that legal framework. It signaled, at minimum, that the science had outrun the policy.
The preclinical research the NCI cited pointed to several mechanisms by which cannabinoids appeared to act on cancer cells. In animal models, researchers observed apoptosis — programmed cell death — triggered by cannabinoid exposure. They also found evidence of anti-angiogenesis, meaning cannabinoids appeared to interrupt the development of the blood vessels that feed tumors. These are not trivial findings. They are the same kinds of mechanisms researchers look for when evaluating any promising oncology candidate.
The NCI also noted that cannabis had shown benefit in managing several symptoms common among cancer patients: pain, nausea, anxiety, and loss of appetite. These palliative effects had already been acknowledged in limited ways through the approval of synthetic cannabinoids. But the lab findings went further, suggesting the plant’s compounds might do more than ease suffering — they might directly interfere with cancer’s survival.
The science behind the acknowledgment
The research the NCI pointed to in 2015 C.E. had been accumulating for years, largely outside the United States. Spanish researchers at Complutense University of Madrid had published influential work on cannabinoids and tumor regression as far back as 2003 C.E. Israeli scientists, building on the foundational endocannabinoid system research of Raphael Mechoulam — who first isolated THC in 1964 C.E. — had been exploring cannabis pharmacology for decades.
Much of this work had been effectively sidelined in the U.S. by the legal barriers surrounding cannabis. Researchers seeking federal funding faced a near-impossible regulatory environment. The NCI’s acknowledgment did not remove those barriers. But it gave scientists, physicians, and advocates a concrete reference point — a government-issued statement they could cite when making the case for expanded research.
It also reflected a broader shift. By 2015 C.E., more than 20 U.S. states had legalized medical cannabis in some form. Public opinion had moved faster than federal policy. The NCI update did not drive that change, but it did represent the federal research apparatus beginning — however cautiously — to catch up.
Lasting impact
The NCI’s acknowledgment helped normalize the conversation about cannabis as a subject of serious oncology research. In the years that followed, the National Institutes of Health expanded funding for cannabinoid research, and several clinical trials examining cannabis compounds in cancer treatment were launched or expanded internationally.
The statement also gave legal and political advocates a durable piece of evidence in ongoing debates about rescheduling cannabis under federal law. If the government’s own cancer institute acknowledged the lab findings, the argument that cannabis had “no accepted medical use” became harder to sustain with a straight face.
For patients — particularly those with terminal diagnoses who had little to lose and were already seeking any available option — the acknowledgment mattered in a different, more personal way. It told them their interest in cannabis was not irrational or desperate. It was supported by evidence the federal government itself had now put in writing.
Blindspots and limits
Lab and animal findings do not automatically translate into effective human treatments. Cannabinoids have shown promise in preclinical settings, but robust, large-scale clinical trials confirming that cannabis effectively treats cancer in humans had not been completed as of 2015 C.E., and the picture remains incomplete today. The NCI was careful to note these limits — the acknowledgment was not an endorsement of cannabis as a cancer cure, and overstating it does a disservice to patients and to the science itself. The structural barriers that limited cannabis research for decades meant the evidence base remained thinner than it could have been, a gap that will take years of rigorous study to close.
Read more
For more on this story, see: Leafly — Government-run cancer institute quietly acknowledges that cannabis kills cancer cells
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Ghana declares its first marine protected area to rescue depleted fish stocks
Ghana’s marine protected area — the country’s first ever — marks a historic turning point for a nation gripped by a quiet fisheries crisis. Established near Cape Three Points in the Western Region, the protected zone restricts or bans fishing activity to allow severely depleted fish populations to recover. Ghana’s coastal stocks have fallen by an estimated 80 percent from historic levels, threatening food security and the livelihoods of millions of small-scale fishers. The declaration also carries regional significance, potentially inspiring neighboring Gulf of Guinea nations to establish coordinated protections of their own.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
Alzheimer’s prevention may have reached a turning point after a landmark trial showed that removing amyloid plaques before symptoms appear can cut the risk of developing the disease by roughly 50%. Researchers at Washington University School of Medicine studied people with rare genetic mutations that make Alzheimer’s nearly inevitable, finding that early, aggressive treatment can genuinely alter the disease’s course. The results, published in The Lancet Neurology, mark the first time any intervention has shown potential to prevent Alzheimer’s from appearing at all, not merely slow its progression. That distinction matters enormously, since amyloid begins accumulating in the brain two…
-
Marie-Louise Eta becomes first female head coach in men’s top-five European leagues
Female head coach Marie-Louise Eta made history on April 11, 2026, when Union Berlin appointed her as interim head coach — becoming the first woman ever to hold a head coaching position in any of men’s top-five European leagues. The Bundesliga club made the move after dismissing Steffen Baumgart, with five matches remaining and real relegation stakes on the line. Eta, 34, had served as assistant coach since 2023 and was already a familiar, trusted presence within the squad. This was no ceremonial gesture — she was handed a survival fight, which is precisely what makes the milestone significant.
